Moleculin Biotech, Inc. (MBRX)

Over the past six months, Moleculin Biotech's stock price has decreased significantly. An independent assessment confirmed no cardiotoxicity of Annamycin. Moleculin obtained a new Australian patent for Annamycin. An analyst decreased the company's price target, while another maintained a 'Buy' recommendation. Short interest in Moleculin Biotech increased. The company reported a net loss for Q3 2025 with limited cash reserves.

As a clinical-stage biopharmaceutical company without commercialized products, Moleculin Biotech does not have traditional demand seasonality. The company's financial health is driven by capital raises and pipeline progress. Stock price data suggests some seasonality in its stock performance.

Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on developing therapies for difficult-to-treat cancers and viruses. Their lead program, Annamycin, is in Phase 3 clinical trials for relapsed or refractory acute myeloid leukemia (AML) and is also in development for soft tissue sarcoma (STS) lung metastases. The WP1066 portfolio targets immune/transcription modulation for brain tumors, pancreatic, and other cancers. WP1122 is an antimetabolite being developed for viruses and certain cancer indications.

Moleculin Biotech, Inc. is headquartered in Houston, Texas, United States. The MIRACLE trial for Annamycin has expanded to 38 sites worldwide, including locations in the United States, Europe, and North Africa.

Moleculin Biotech's brand reputation has been mixed, influenced by stock price declines and positive clinical developments. The stock has seen a substantial drop over the last 12 months. Positive clinical trial results and a new Australian patent for Annamycin have positively affected its reputation.

The ownership structure of Moleculin Biotech is a mix of institutional, retail, and individual investors. Approximately 15.52% of the stock is owned by institutional investors, including Armistice Capital LLC, Vanguard Group Inc, UBS Group AG, Newbridge Financial Services Group, Inc., and CVA Family Office, LLC. WALTER V KLEMP owns the most shares among individual investors.